Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061768 | 0.82 | GSR (0.44) | NOS3NOS1NOS2DDAH1 | |
| SCHEMBL28762352 | 0.76 | CA1 (0.38) | — | |
| SCHEMBL16330498 | 0.74 | ZDHHC7 (0.45) | NOS3NOS1NOS2LTA4HDDAH1 | |
| SCHEMBL3061754 | 0.74 | MC4R (0.34) | — | |
| SCHEMBL3074274 | 0.74 | MC4R (0.34) | — | |
| SCHEMBL4602594 | 0.74 | LTA4H (0.39) | NOS3NOS1NOS2LTA4H | |
| SCHEMBL3087112 | 0.74 | — | — | |
| SCHEMBL4602597 | 0.74 | LTA4H (0.39) | NOS3NOS1NOS2LTA4H | |
| SCHEMBL27405459 | 0.73 | ZDHHC7 (0.48) | NOS3NOS1NOS2LTA4HDDAH1 | |
| SCHEMBL27405457 | 0.73 | ZDHHC7 (0.48) | NOS3NOS1NOS2LTA4HDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790926-B2 | Alpha, omega-difunctional aldaramides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7351862-B2 | Alpha, omega-difunctional aldaramides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1853554-A2 | ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060258886-A1 | Alpha, omega-difuctional aldaramides | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| WO-2006091902-A2 | ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258886-A1 | Alpha, omega-difuctional aldaramides | FADS2, FASN, DEGS1 | NOS3 2233/4885NOS1 2344/4885NOS2 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.